Tagged with EMA

Janssen PharmaBoardroom recently sat down with Janssen EMEA head Kris Sterkens, who outlined the enduring importance of Europe to the global group, even with the emergence of Asian power markets such as China and the continuing significance of the USA. Read the full interview here.   Where Europe really does excel…

Spain Ines Perea, general manager for Spain and Portugal at Jazz Pharmaceuticals, a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options in the areas of sleep and hematology/oncology, discusses her progress over the last 14 months in nurturing the local affiliate and the importance…

France Franck Cousserans, general manager of France and Belgium at Jazz Pharmaceuticals, highlights the company’s key products and the challenges of market access in France. Furthermore, he indicates the steps needed to grow in the future and how Jazz’s corporate culture is key to its success.   In the US, Jazz…

Brexit Despite a myriad of uncertainties around its decision to leave the European Union, the UK still stands as one of the world’s premier life science investment destinations. With heavyweight medical science infrastructure and a well-earned reputation for elite-level innovation, the key industry stakeholders featured in our UK report, explore how…

Brexit The European Medicines Agency has cut Britain out of its contracts 7 months ahead of Brexit. “You might have been working on a cancer drug for decades and built up so much expertise that you are the absolute specialist in your field and now have to transfer all your knowledge…

Spain With Spain now on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top investment destination once more thanks to a much-improved market access scenario, high-quality but affordable manufacturing capabilities and an enviable human resource base. As…

Spain Eduardo Lopez-Puertas, managing director of IFEMA, Spain’s largest and most successful congress center, discusses the country’s competitive advantages compared to the rest of Europe, and the role the pharmaceutical sector plays in their strategy to contribute to Spain’s economy. Can you please introduce IFEMA to our international readers and its…

UK UK pharmaceutical and biotech companies are already finding it increasingly difficult to attract talent from overseas. Additionally, UK firms are looking to poach EMA staff as it heads to Amsterdam from London following Brexit. Following the Brexit vote, the UK is already seeing problems in filling senior positions at life…

EMA The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following three rounds of voting. “We are delighted, it was very tight, it was nerve-wracking, to be honest” Halbe Zijlstra, Minister…

Austria Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human protein products manufacturer in the world, discuss the strategic significance of Austria to the group, the nation’s historical excellence in plasma and hematology, and recent upgrades to the affiliate’s manufacturing and fractionation capabilities Vienna…

Bulgaria Assena Stoimenova, member of the management board of the European Medicines Agency (EMA) and executive director of the Bulgarian Drug Agency (BDA), explains the Agency’s evolution under her tenure as well as her commitment to ensuring that the BDA remains predictable, transparent and fair, being fully focused on safeguarding patients…

Brazil Dr. Wilson Pedreira, executive director of the Oncology and Hematology Center of the Albert Einstein Philanthropic Society in Brazil provides insights into the innovative healthcare model implemented in this cutting edge cancer center, which proudly stood as the first of its kind outside the US to integrate the prestigious MD…